单胎妊娠中全基因组无创产前筛查提示15三体阳性的临床意义及与妊娠结局的关联:前瞻性队列研究、系统综述与Meta分析
该研究纳入香港单中心2020年1月至2023年4月接受全基因组NIPS的单胎妊娠36466例,10例(0.027%)筛查阳性。结合29项研究30个队列175例阳性病例的Meta分析显示,胎儿15三体合并PPV为17.4%,母源性UPD15占20.3%,68.4%出现不良妊娠结局。作者建议对NIPS提示15三体阳性者强烈推荐羊膜腔穿刺确诊。
要点
- 全基因组NIPS筛查15三体的阳性率低(本队列0.027%),胎儿15三体合并PPV仅17.4%。
- NIPS阳性者中母源性UPD15占20.3%,胎儿核型正常后UPD15残留风险至少11.3%。
- 作者建议对NIPS提示15三体阳性者强烈推荐羊膜腔穿刺以排查UPD15和真性胎儿嵌合体。
核心结论
- 全基因组NIPS对15三体的PPV相对较低,但阳性病例中相当比例存在母源性UPD15或胎儿嵌合体,需羊膜腔穿刺确诊。
- 作者建议对任何NIPS提示15三体阳性的病例强烈推荐羊膜腔穿刺,以排查UPD15和真性胎儿嵌合体并指导后续临床管理。
研究设计与样本
- 前瞻性队列研究,纳入香港单中心2020年1月至2023年4月接受全基因组NIPS的单胎妊娠36466例。
- 系统综述与随机效应Meta分析纳入29项研究的30个队列,共175例NIPS提示15三体阳性的妊娠,包括本前瞻性队列。
主要发现
- 本队列36466例单胎妊娠中10例(0.027%)NIPS提示15三体阳性(每1万例单胎妊娠2.7例),PPV为40.0%(4/10),3/10(30.0%)证实为母源性UPD15。
- 26个队列(筛查总例数明确)的合并发生率为145/1009301(0.013%,95%CI 0.009-0.019%;I²=78.4%),即每1万例单胎妊娠1.3例;孕早期筛查者合并发生率显著高于孕中期筛查者。
- 102例有侵入性诊断结果者中22例确诊胎儿15三体(8例完全型15三体,14例真性胎儿嵌合体),胎儿15三体的合并PPV为17.4%(95%CI 4.0-35.0%;I²=51.5%)。
- 69例有UPD15检测结果者中14例(20.3%)为母源性UPD15;假定未检测UPD15的二倍体病例均为正常双亲遗传,胎儿15三体或UPD15的合并PPV为32.6%(95%CI 14.4-53.0%;I²=55.3%),胎儿核型正常后UPD15残留风险至少11.3%。
- 有临床随访者中68.4%发生不良妊娠结局,包括胎儿丢失(29.1%)、终止妊娠(21.5%)和/或妊娠并发症(17.7%)。
关键数值与推荐
- 本队列全基因组NIPS筛查15三体的阳性率为0.027%(2.7/10000单胎妊娠),PPV为40.0%(4/10)。
- Meta分析合并发生率为0.013%(95%CI 0.009-0.019%;I²=78.4%),即1.3/10000单胎妊娠。
- 胎儿15三体合并PPV为17.4%(95%CI 4.0-35.0%;I²=51.5%);胎儿15三体或UPD15合并PPV为32.6%(95%CI 14.4-53.0%;I²=55.3%)。
- 母源性UPD15占20.3%(14/69),胎儿核型正常后UPD15残留风险至少11.3%。
- 作者建议对NIPS提示15三体阳性者强烈推荐羊膜腔穿刺。
临床怎么用
- 作者建议对任何NIPS提示15三体阳性的病例强烈推荐羊膜腔穿刺,以排查UPD15和真性胎儿嵌合体并指导后续临床管理。
局限性
- UPD15合并PPV的估算假定未检测UPD15的二倍体病例均为正常双亲遗传。
- 合并发生率分析存在异质性(I²=78.4%),胎儿15三体PPV分析存在异质性(I²=51.5%),胎儿15三体或UPD15合并PPV分析存在异质性(I²=55.3%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the incidence and clinical significance of a positive result on genome-wide non-invasive prenatal screening (NIPS) for trisomy 15. METHODS: We conducted a prospective cohort study of singleton pregnancies that underwent genome-wide NIPS at a single center in Hong Kong between January 2020 and April 2023. The incidence of a positive genome-wide NIPS result for trisomy 15, positive predictive value (PPV) for trisomy 15 and risk of uniparental disomy 15 (UPD15) were assessed based on cytogenetic and molecular analyses at amniocentesis. Adverse fetal outcomes were reviewed. Furthermore, a systematic review of cohort studies reporting positive trisomy 15 results from genome-wide NIPS was performed, including data from our prospective cohort. Random-effects meta-analysis was used to obtain pooled estimates of incidence and PPV. The risk of UPD15 and adverse pregnancy outcomes was also evaluated. Heterogeneity was evaluated using Higgins' I2 statistic. RESULTS: In our cohort of 36 466 singleton pregnancies that underwent genome-wide NIPS, 10 (0.027%) cases were screen-positive for trisomy 15 (2.7 per 10 000 singleton pregnancies). Results from invasive diagnostic testing were available for all screen-positive cases. The PPV of genome-wide NIPS for trisomy 15 was 40.0% (4/10), and 3/10 (30.0%) cases were confirmed to have maternal UPD15. Together with our study, a total of 30 cohorts from 29 studies were included in the systematic review and meta-analysis, comprising 175 pregnancies that were screen-positive for trisomy 15. In 26 cohorts in which the total number of cases screened using NIPS were specified, the pooled incidence of trisomy 15 was 145/1 009 301 (0.013% (95% CI, 0.009-0.019%; I2 = 78.4%)), or 1.3 per 10 000 singleton pregnancies. The pooled incidence was significantly higher among women screened in the first trimester compared with those tested in the second trimester. Among 102 cases with a diagnostic result from invasive testing, 22 were confirmed as having fetal trisomy 15, including eight with full trisomy 15 and 14 with true fetal mosaicism. The pooled PPV for fetal trisomy 15 was 17.4% (95% CI, 4.0-35.0%; I2 = 51.5%). Among 69 cases with a result from UPD15 testing, 14 (20.3%) had maternal UPD15. Assuming that all diploid cases that did not undergo UPD15 testing had normal biparental inheritance of chromosome 15, the pooled PPV for either fetal trisomy 15 or UPD15 was 32.6% (95% CI, 14.4-53.0%; I2 = 55.3%), and the residual risk of UPD15 after a fetal normal karyotype was at least 11.3%. Among patients with clinical follow-up, 68.4% experienced an adverse pregnancy outcome, including fetal loss (29.1%), termination of pregnancy (21.5%) and/or pregnancy complication (17.7%). CONCLUSIONS: Although the PPV of genome-wide NIPS for fetal trisomy 15 was relatively low, a significant proportion of cases with a positive NIPS result for trisomy 15 had maternal UPD15 or fetal mosaicism, underscoring the need for diagnostic confirmation via amniocentesis. Amniocentesis should be strongly recommended for any case with a positive NIPS result for trisomy 15 to investigate UPD15 and true fetal mosaicism and guide subsequent clinical management. © 2025 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Xue S, Zheng Y, Cao Y, et al. Clinical significance and association with pregnancy outcome of positive non-invasive prenatal screening for trisomy 15 in singleton pregnancy: prospective cohort study, systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2025. PMID: 41118657. doi:10.1002/uog.70106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。